Gliklazid MB Pharmstandard, 60 mg 30 pcs

Orderal hypoglycemic agent, sulfonylurea derivative of the II generation. Stimulates insulin secretion by pancreatic β-cells. Increases the sensitivity of peripheral tissues to insulin. Apparently stimulates activity of intracellular enzymes (in particular, muscle glycogen synthetase). Reduces the time interval from the moment of food intake to the beginning of insulin secretion. Restores the early peak of insulin secretion, reduces the postprandial peak of hyperglycemia.

Glyclazide reduces platelet adhesion and aggregation, slows the development of parietal thrombus, increases vascular fibrinolytic activity. It normalizes vascular permeability.

It has anti-atherogenic properties: lowers the blood concentration of total cholesterol (CH) and LDL, increases the concentration of HDL and reduces the amount of free radicals. Prevents the development of microthrombosis and atherosclerosis. Improves microcirculation. Reduces the sensitivity of blood vessels to adrenaline.

In diabetic nephropathy with long-term use of gliclazide there is a significant reduction of proteinuria.

Indications

Type 2 diabetes

Type 2 diabetes mellitus with insufficient effectiveness of diet therapy, physical activity and weight reduction.

Prevention of complications of type 2 diabetes: reducing the risk of microvascular (nephropathy, retinopathy) and macrovascular complications (myocardial infarction, stroke).

Active ingredient

Gliclazide

How to take, the dosage

The initial daily dose is 80 mg, the average daily dose is 160-320 mg, the frequency of administration is 2 times a day before meals.

Interaction

Gliclazide increases the effect of anticoagulants (warfarin), correction of anticoagulant dose may be required.

Special Instructions

Treatment with Gliclazide MB tablets is carried out only in combination with low-calorie, low-carbohydrate diet. It is necessary to monitor blood glucose content regularly on an empty stomach and after meals, especially during the first days of treatment with the drug.

Contraindications

– hypersensitivity to gliclazide or any of the excipients of the drug, to other sulfonylurea derivatives, to sulfonamides;
– diabetes mellitus type 1;
– diabetic ketoacidosis, diabetic precoma, diabetic coma; . – severe renal and/or hepatic failure;
– pregnancy and lactation period;
– age under 18 years;
– taking miconazole;
– congenital lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

It is not recommended to use the drug simultaneously in combination with phenylbutazone or danazol.

Side effects

Hypoglycemia (in case of violation of the dosing regimen and inadequate diet): headache, increased fatigue, feeling of hunger, increased sweating, sudden weakness, palpitations, arrhythmias, increased blood pressure, drowsiness, insomnia, agitation, aggressiveness, anxiety, irritability, impaired concentration, inability to concentrate and slow reaction time, depression, visual impairment, aphasia, tremor, paresis, sensory disturbances, dizziness, feelings of helplessness, loss of self-control, delirium, seizures, shallow breathing, bradycardia, loss of consciousness, coma.

Overdose

Symptoms: hypoglycemia, impaired consciousness, hypoglycemic coma.

Similarities

Diabeton MB, Glidiab, Diabefarm MB, Gliclazid MB, Diabetalong, Gliclazid Canon, Gliclazid, Golda MB